This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu
Trial record 1 of 2 for:    ath434
Previous Study | Return to List | Next Study

Biomarker Study of ATH434 in Participants With MSA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05864365
Recruitment Status : Enrolling by invitation
First Posted : May 18, 2023
Last Update Posted : February 7, 2024
Information provided by (Responsible Party):
Alterity Therapeutics

Brief Summary:
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

Condition or disease Intervention/treatment Phase
Multiple System Atrophy Drug: ATH434 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy
Actual Study Start Date : May 23, 2023
Estimated Primary Completion Date : February 14, 2025
Estimated Study Completion Date : February 28, 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ATH434 Drug: ATH434
ATH434 taken by mouth two times per day

Primary Outcome Measures :
  1. Change in iron content as measured by brain MRI [ Time Frame: Change from Baseline to Week 52 ]

Secondary Outcome Measures :
  1. Change in Aggregating alpha-Synuclein Levels [ Time Frame: Change from Baseline to Week 52 ]
  2. Change in Neurofilament Light Chain Levels [ Time Frame: Change from Baseline to Week 52 ]
  3. Change in Unified MSA Rating Scale (UMSARS) Score [ Time Frame: Change from Baseline to Week 52 ]
  4. Change in 36-Item Short Form Survey (SF-36) Score [ Time Frame: Change from Baseline to Week 52 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participant has clinical features of parkinsonism.
  2. Participant has evidence of orthostatic hypotension and/or bladder dysfunction.
  3. Participant has ataxia and/or pyramidal signs on neurological examination.
  4. Participant has biomarker evidence of MSA in biologic fluid and on MRI.

Exclusion Criteria:

  1. Participant is unable to swallow study drug.
  2. Participant is unable to attend study visits or complete study procedures.
  3. Participant has structural brain abnormality on MRI.
  4. Participant has any significant neurological disorder other than MSA.
  5. Participant has an unstable medical or psychiatric illness.
  6. Participant has a contraindication to, or is unable to tolerate, MRI or lumbar puncture.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05864365

Layout table for location information
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Alterity Therapeutics
Layout table for additonal information
Responsible Party: Alterity Therapeutics Identifier: NCT05864365    
Other Study ID Numbers: ATH434-202
First Posted: May 18, 2023    Key Record Dates
Last Update Posted: February 7, 2024
Last Verified: February 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alterity Therapeutics:
Multiple System Atrophy
Neurodegenerative disease
Shy-Drager Syndrome
Movement disorders
Autonomic dysfunction
Atypical parkinsonism
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple System Atrophy
Shy-Drager Syndrome
Pathological Conditions, Anatomical
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Vascular Diseases
Cardiovascular Diseases